Growing community of inventors

Shanghai, China

Jifeng Duan

Average Co-Inventor Count = 6.39

ph-index = 3

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 20

Jifeng DuanXiaoqiang Yan (13 patents)Jifeng DuanWeihan Zhang (13 patents)Jifeng DuanYu Cai (8 patents)Jifeng DuanTao Wang (6 patents)Jifeng DuanWei-Guo Su (6 patents)Jifeng DuanYumin Cui (5 patents)Jifeng DuanYongxin Ren (5 patents)Jifeng DuanZhiming Ma (5 patents)Jifeng DuanHong Jia (4 patents)Jifeng DuanYang Sai (2 patents)Jifeng DuanWeiguo Su (2 patents)Jifeng DuanTao Wang (2 patents)Jifeng DuanJifeng Duan (13 patents)Xiaoqiang YanXiaoqiang Yan (28 patents)Weihan ZhangWeihan Zhang (24 patents)Yu CaiYu Cai (97 patents)Tao WangTao Wang (109 patents)Wei-Guo SuWei-Guo Su (33 patents)Yumin CuiYumin Cui (11 patents)Yongxin RenYongxin Ren (9 patents)Zhiming MaZhiming Ma (6 patents)Hong JiaHong Jia (13 patents)Yang SaiYang Sai (5 patents)Weiguo SuWeiguo Su (3 patents)Tao WangTao Wang (2 patents)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Hutchison Medipharma Enterprises Limited (11 from 15 patents)

2. Nutrition Science Partners Limited (2 from 3 patents)


13 patents:

1. 8901143 - Pyrimidine derivatives

2. 8557302 - [object Object]

3. 8557308 - [object Object]

4. 8497372 - Use of substituted quinazoline compounds in treating age-related macular degeneration

5. 8349859 - Pyrimidine derivatives

6. 8212033 - Use of substituted quinazoline compounds in treating angiogenesis-related diseases

7. RE43423 - Crude extracts from

8. RE42718 - Crude extracts from andrographis paniculata

9. 7902359 - Decahydronaphthalene compounds

10. 7829574 - Substituted quinazoline compounds and their use in treating angiogenesis-related diseases

11. 7622465 - Costunolide derivatives

12. 7488836 - Costunolide derivatives

13. 7341748 - [object Object]

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
1/21/2026
Loading…